{
    "medicine_id": "6f970cffdb6a02a66e62654c43f2a1fa6f5fde33",
    "platform_id": "DB00768",
    "metadata": {
        "name": "Act Olopatadine 0 1 2 mg Solution",
        "composition": "2 mg Olopatadine",
        "clinical_particulars": {
            "therapeutic_indications": "Olopatadine is indicated for the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solution L6781 In nasal spray olopatadine is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and older L6784",
            "contraindications": {
                "disease": "Based on the findings of an acute toxicity study in animals the oral LD sub 50 sub of olopatadine was 1150 mg kg in mice and 3870 mg kg in rats L6790 The Lowest published toxic dose via the oral route was 20 mg kg in rat and 0 1 mg kg in mouse MSDS There are no known reports on overdosage following oral ophthalmic or intranasal administration of olopatadine Likely symptoms of antihistamine overdose may include drowsiness in adults and initially agitation and restlessness followed by drowsiness in children In case of suspected overdose supportive and symptomatic treatment is recommended L6784",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Inflammatory reactions in response to various stimuli are mediated by endogenous mediators and other pro inflammatory factors Histamine receptor activation and mast cell degranulation are primary mechanisms that cause inflammatory reactions such as ocular itching hyperemia chemosis eyelid swelling and tearing of seasonal allergic conjunctivitis A179704 Olopatadine is an anti allergenic molecule and mast cell stabilizer that inhibits the _in vivo_ type 1 immediate hypersensitivity reaction L6790 By blocking the effects of histamine olopatadine works to reduce the symptoms of allergies and inflammation at various sites of administration including the eyes and nose It has shown to exert antihistaminic effects in isolated tissues animal models and humans L6784 Olopatadine also demonstrated dose dependent inhibition of immunologically stimulated release of histamine from rat basophilic leukemia cells and human conjunctival mast cells _in vitro_ A179704 Olopatadine has a relatively rapid onset of action and prolonged duration where it was shown to mediate anti histaminic effects at 5 minutes to 24 hours post administration A179704 While olopatadine is a non sedating antihistamine agent there have been reports of somnolence in some patients taking nasal olopatadine during clinical trials L6784 Temporary blurred vision or other visual disturbances were observed following ophthalmic administration Olopatadine has negligible effects on alpha adrenergic dopamine muscarinic type 1 and 2 and serotonin receptors L6790 In clinical trials there was no evidence of any effect of olopatadine on QT prolongation was observed following intranasal administration L6784",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}